Roman V. Donskikh

Roman V. Donskikh

Auto-generated profile, based on publicly available information

Roman V. Donskikh

N.N. Petrov National Medical Research Center of Oncology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ATA. I. Tseluiko
A. I. Tseluiko
IBI. A. Baldueva
I. A. Baldueva
TNT. L. Nekhaeva
T. L. Nekhaeva
AAA. S. Artemyeva
A. S. Artemyeva
АКАсель Кудайбергенова
Асель Кудайбергенова
ABA. M. Belyaev
A. M. Belyaev
Immuno-oncology is a rapidly developing field in medicine. Drug combination therapies have already been studied in many clinical trials of different types of tumours. In recent years, a checkpoint inhibition therapy with monoclonal antibodies that target cytological T-lymphocytes has been developed. Thus, inhibition of two regulator genes CTLA 4 and PD1 or PD-L1 ligand to it is able to restore mediated T-cell tumour regression in its many localizations. The article considers a number of key fields of immunology and immunotherapy through a specific example of breast cancer (BC): the role of T-lymphocytes, vaccines, biomarkers of immunotherapy. The treatment used by the authors was based on an innovative technology of autologous dendritic cell-based vaccine based on highly immunogenic cancer/testis antigens (CTA) for immunotherapy of malignant tumours. The technology of specific CTA+-activated autologous dendritic cells (DC)-based immunotherapy was chosen as an innovative solution for the treatment of breast cancer patients. The treatment results showed that a clinically significant anti-tumour effect was achieved in 73.7% of patients. Median disease-free survival was 8.3 months (95% Cl 6.5-9.9 months), no grade 3-4 complications were recorded, grade 1-2 complications were observed in 57% of patients. The immunological effect in laboratory tests was recorded in 92% of patients. Thus, autologous DCs loaded with cancer/testis antigens can be considered as palliative dendritic vaccine therapy in patients with metastatic breast cancer who have exhausted standard treatment options. Also, the authors presented the results of immunological studies of the prognostic and predictive significance of the immunological response from the perspective of pathomorphology and general immunology, including tumour-infiltrating T-lymphocytes (TILs, CD3, CD4, CD8), their quantitative ratio and correlation with regulatory genes (PD-1, PD- L1, FOX-P3). The results of overall analysis comprising data of 2,148 patients from 9 centers confirmed the strong prognostic role of stromal tumour-infiltrating lymphocytes (sTILs) in early triple-negative breast cancer.

1 November 2023 in Voprosy onkologii
Verified
Journal Article
Open access
БКБорис Сергеевич Каспаров
Борис Сергеевич Каспаров
ДКДенис Викторович Ковлен
Денис Викторович Ковлен
ТСТатьяна Юрьевна Семиглазова
Татьяна Юрьевна Семиглазова
КККристина Орхановна Кондратьева
Кристина Орхановна Кондратьева
ГПГеннадий Николаевич Пономаренко
Геннадий Николаевич Пономаренко
АБАлексей Михайлович Беляев
Алексей Михайлович Беляев
An increase in the life expectancy of resectable non-small cell lung cancer (NSCLC) patients after complex treatment is associated with psychological and physical impairments that reduce the overall quality of life. The article evaluates the efficacy of rehabilitation programs in NSCLC patients, considering recommended technologies (RT) of physical and rehabilitation medicine (personalized approach) in comparison to standard rehabilitation methods. Materials and methods. The study included 240 patients with resectable NSCLC aged 45 to 71 years (median 60.2 years) who underwent rehabilitation as part of combined/complex treatment at the N.N. Petrov NMRC of Oncology between 2017 and 2022. Patients in the experimental group received personalized rehabilitation, while the control group underwent standard rehabilitation. The control group patients were paired based on key characteristics, including gender, age, functional status, histological subtype, disease stage, and treatment volume. The dynamics of patient parameters were evaluated in the pre-/post-operative period, immediately after implementing the rehabilitation programs, and one year later. The evaluation included an assessment of clinical status indicators (mMRC scale, COMP scale, VAS, 6-minute walk test), functional (PFTs) and psychophysiological parameters (MFI-20 scale, HADS scale), as well as quality of life indicators (EORTC-QLQ30). Results. Analysis of rehabilitation effectiveness in NSCLC patients showed that the personalized rehabilitation model in the experimental group was effective in 86 % of cases, whereas standard rehabilitation programs in the control group were effective in 76 % of cases. The main determinants influencing the therapeutic effect following the application of rehabilitation programs tailored to the selected RTs are: the parameters of external respiration function (VC – vital capacity, PEFR – peak expiratory flow rate, MEF – mean expiratory flow rate), the 6-minute walk test, dyspnea severity scales (Modified Medical Research Council, mMRC), and activities of daily living (Canadian Occupational Performance Measure, COMP). Conclusion. Identified determinants will allow for the early prediction of the effectiveness of rehabilitation technologies in specific models of resectable NSCLC patients, taking into account initial parameters. Увеличение продолжительности жизни больных операбельным немелкоклеточным раком легкого (НМРЛ) после комплексного лечения сопряженно с нарушениями психологического и физического функционирования, снижающими общее качество жизни. В статье приводится оценка эффективности реабилитационных программ у больных операбельным НМРЛ с учётом рекомендованных технологий (РТ) физической и реабилитационной медицины (персонализированный подход) в сравнении со стандартным подходом к реабилитации. Материалы и методы. В исследование были включены 240 пациентов с операбельным НМРЛ в возрасте от 45 до 71 года (медиана 60,2 года), получавших реабилитацию в рамках комбинированного/комплексного лечения в ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России в период с 2017 по 2022 гг. Пациентам в экспериментальной группе применялась персонализированная модель реабилитации. Согласно дизайну исследования в контрольную группу (стандартные реабилитационные мероприятия) были подобраны попарно пациенты, соответствующие больным экспериментальной группы по основным характеристикам: полу, возрасту, функциональному состоянию, гистологическому подтипу, стадии заболевания, объёму лечения. Динамика показателей пациентов была исследована в пред-/послеоперационный период, непосредственно после реализации программ реабилитации и через 1 год, включала оценку показателей клинического статуса (Шкала mMRC, Шкала COMP, ВАШ, 6-минутный тест ходьбы), функциональных (ФВД) и психофизиологических показателей (Шкала MFI-20, Шкала HADS), показателей качества жизни (EORTC-QLQ30). Результаты. Анализ показателей эффективности реабилитации больных НМРЛ показал, что в экспериментальной группе (персонализированная модель реабилитации), реабилитация была эффективна у 86 % пациентов, в то время как в контрольной группе (стандартные программы реабилитации) — в 76 % случаев. Основными детерминантами, влияющими на формирование лечебного эффекта после применения реабилитационных программ, составленных с учётом...

6 May 2024 in Voprosy onkologii
Verified
Journal Article
Open access
ПКПетр Владимирович Криворотько
Петр Владимирович Криворотько
NANikolay Amirov
Nikolay Amirov
АААнна Сергеевна Артемьева
Анна Сергеевна Артемьева
ЕБЕкатерина Александровна Бусько
Екатерина Александровна Бусько
ТТТенгиз Тенгизович Табагуа
Тенгиз Тенгизович Табагуа
АБАлексей Михайлович Беляев
Алексей Михайлович Беляев
Introduction. Current opinion is that surgery is diagnostic rather than curative and does not affect long-term outcomes in breast cancer (BC) patients with complete pathomorphological response (pCR) after neoadjuvant systemic therapy (NST). As a minimally invasive method for diagnosing pCR in BC, vacuum-assisted biopsy (VAB) of the tumour bed has shown promising results. This paper presents a retrospective analysis of the outcomes of patients with triple-negative and HER2-positive BC who achieved pCR after NST according to different types of invasive breast surgery, including patients who underwent VAB alone without subsequent breast surgery. Materials and methods. From 1 January 2021 to 1 July 2023, we analysed 3247 patients who underwent surgery at the Department of Breast Tumours at the N.N. Petrov NMRC of Oncology. Patients were included in the study if they had unifocal invasive HER2+ and TNBC (cT1-2N0-1M0) with histologically confirmed pathological complete response (ypT0N0) to NST. Exclusion criteria were an intraductal component detected by trephine bone marrow core biopsy and germline mutations in BRCA1/2. According to the planned analysis, all patients were divided into three groups: the breast-conserving surgery (BCS) group, the mastectomy (ME) group and the VAB group. Primary endpoint was 2-year ipsilateral breast tumour recurrence-free survival [IBTR-FS]. Secondary endpoints included 2-year disease-free survival (DFS) and complication rates. Results. Of the 3 247 patients analyzed, 81 patients who met the inclusion criteria were included in the final analysis. There were 39 patients in the BCS group, 19 patients in the ME group, and 23 patients in the VAB group. The median follow-up was 24 months. The median survival was not reached for any of the endpoints. 2-year IBTR-FS was 100 % in the BCS group vs. 100 % in the ME group vs. 91.3 % in the VAB group [p = 0.159]. 2-year DFS was 97.4 % in the BCS group vs 94.7 % in the ME group vs 87.0 % in the VAB group [p = 0.396]. There was no difference in the hazard ratio (HR) for recurrence between the different types of surgery. When measuring HR adjusted for lymph node status (cN) and disease stage, there was a statistically significant higher risk in the VAB group [HR adjusted for cN: 12.236, (95 % CI, 1.163-128.773), p = 0.037; HR adjusted for stage: 17.071, (95 % CI, 1.255-232.173), p = 0.033]. Conclusion. To determine the safety of VAB use, further observational studies and large randomised prospective trials are needed. There was no significant difference in the incidence of complications between the different types of invasive procedures in this cohort of patients. Введение. В настоящее время существует точка зрения, согласно которой у пациентов с диагнозом рак молочной железы (РМЖ) выполнение хирургического вмешательства при достижении полного патоморфологического ответа (pCR) после неоадъювантной системной терапии (НСТ) носит диагностический, а не лечебный характер, и не влияет на отдаленные результаты лечения. Вакуум-ассистированная биопсия (ВАБ) ложа опухоли при РМЖ показала многообещающие результаты в качестве малоинвазивного метода диагностики pCR. В этой работе представлен ретроспективный анализ результатов лечения пациентов с трижды-негативным и HER2-позитивным РМЖ, достигших pCR после НСТ, в зависимости от различных видов инвазивного вмешательства на молочной железе, включая пациентов, которым была проведена только ВАБ без последующего хирургического вмешательства на молочной железе. Материалы и методы. За период с 01 января 2021 г. по 01 июля 2023 г. проанализировано 3 247 пациентов, которым выполнено хирургическое вмешательство в отделении опухолей молочной железы на базе ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России. В исследование включались пациенты с унифокальным инвазивным HER2+ и ТНРМЖ (cT1–2N0–1M0), у которых гистологически подтвержден полный патоморфологический ответ (ypT0N0) на НСТ. В анализ не включались пациентки в случае выявления внутрипротокового компонента, по данным трепан-биопсии, а также в случае носительства наследственных мутаций в генах BRCA1/2. В соответствии с запланированным анализом все пациенты были разделены на три группы: группа органосохраняющих операций (ОСО), группа мастэктомий (МЭ), группа ВАБ. В качестве первичной конечной точки оценивалась двухлетняя выживаемость без рецидива в ипсилатеральной молочной железе [IBTR-FS]. Вторичные конечные точки включали двухлетнюю безрецидивную выживаемость (DFS) и частоту...

30 July 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
VSV. F. Semiglazov
V. F. Semiglazov
MDM. A. Dzhelialova
M. A. Dzhelialova
SYS. S. Yerechshenko
S. S. Yerechshenko
EME. T. Munaeva
E. T. Munaeva
RPR. S. Pesotsky
R. S. Pesotsky
ПКП. В. Криворотько
П. В. Криворотько
Achieving a pathologic complete response as a result of neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial showed a significant survival improvement with capecitabine treatment of patients with residual invasive disease following neoadjuvant chemotherapy, and the KATHERINE trial demonstrated a significant benefit of trastuzumabemtansine (TDM1) in patients with HER2-positive breast cancer who did not achieve a pathologic complete response, so we have a lot of interesting alternatives of post-neoadjuvant treatments for high-risk patients. The discovery of molecular markers of resistance to endocrinotherapy (cyclin-dependent kinases (CDK 4/6), ER mutation (ESR1), mTOR signaling pathway, co-expression of ER+/HER2+) and inhibitors to them expanded the possibilities of endocrinotherapy not only in advanced and metastatic breast cancer, but also in residual ER+ tumors. The pCR rates in hormone receptor-positive breast cancer after neoadjuvant chemotherapy are around 10%, which is much lower than the values observed in HER2-positive and triple negative subtypes, so new strategies are needed to improve pCR rates in this subgroup, even though the adjuvant endocrine therapy impacts significantly the outcomes of this patients. The cyclin-dependent kinases (CDKs) are serine–threonine kinases that regulate cell cycle progression from the G1 to the S-phase during mitosis. CDKs activity can be abnormally increased or dysregulated in breast cancer, leading to a constant stimulus for cell proliferation and survival, which is a known mechanism of resistance to endocrine treatment. The CDK inhibitors act on CDKs and block their activity, thereby restoring the cell cycle regulation. In studies with metastatic hormone receptor-positive breast cancer patients, the combination of a CDKis with first or second-line endocrine therapy showed significant improvements in progression-free survival and response rates. Evolving techniques such as next-generation sequencing and gene expression profiles have improved our understanding of the biology of residual disease and also the mechanisms involved in treatment resistance.

5 May 2023 in HERALD of North-Western State Medical University named after I.I. Mechnikov
Verified
Journal Article
Closed access
PDF file
NANikolay Amirov
Nikolay Amirov
PKPetr V. Krivorotko
Petr V. Krivorotko
VMViktoria V. Mortada
Viktoria V. Mortada
RDRoman V. Donskikh
Roman V. Donskikh
RPRoman S. Pesotskiy
Roman S. Pesotskiy
БМБеляев Алексей Михайлович
Беляев Алексей Михайлович
BACKGROUND: Neoadjuvant systemic therapy for triple-negative and HER2-positive breast cancer can achieve a complete pathologic response in approximately 60% of patients. Pathological complete response to neoadjuvant systemic therapy is a predictive factor consistent with a positive prognosis which can be accurately determined by percutaneous vacuum aspiration biopsy. AIM: To evaluate the amount of surgery in the group of patients with triple-negative and HER2-positive early breast cancer whose complete pathologic response was confirmed by vacuum aspiration biopsy and who did not undergo standard surgery. MATERIALS AND METHODS: The following single-centre study has been conducted in the Russian Federation. Women aged 18 years old and older with unicentric (cT1-2N0-1M0 by classification TNM) triple-negative or HER2-positive breast cancer with complete clinical response after neoadjuvant systemic therapy according to imaging diagnostic methods. The patients underwent vacuum aspiration biopsy on the mammary gland under ultrusound control with standard amount of surgical intervention on the axillary region. In case when no invasive or in situ disease was detected, no further breast surgery was performed and the patients underwent standard radiation therapy. The survival with no tumor relapse in the ipsilateral mammary gland was assessed as the primary endpoint. The study is registered on сlinicaltrials.gov, NCT04293796. RESULTS: Between June 2020 and May 2022, twenty-seven (84.4%) patients (all women; mean age 47.5 (3268) years) were enrolled in the study and underwent visually controlled vacuum aspiration biopsy. The average initial tumor size was 20.5 (735) mm. 7 (25.9%) patients initially had metastases in the axillary lymph nodes confirmed by puncture biopsy; 15 (55.6%) patients had HER2-positive breast cancer, and 12 (44.4%) had triple-negative breast cancer. A study of vacuum aspiration biopsy samples showed that 6 (22.2%) patients had a residual tumor, and 21 (77.8%) patients achieved complete pathologic response (95% confidence interval 53.2 to 81.4). At a median follow-up of 12.4 months, there were no tumor relapses in the ipsilateral mammary gland in 21 patients with complete pathologic response confirmed by vacuum aspiration biopsy after neoadjuvant systemic therapy, as well as other relapses or progression of the disease. CONCLUSIONS: The patients with a complete pathologic response, which is confirmed by the vacuum aspiration biopsy method, who refused to perform surgery on the mammary gland do not demonstrate worse results with a short period of observation. However, additional prospective clinical studies are needed.

9 May 2024 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
DED. A. Enaldieva
D. A. Enaldieva
ПКП. В. Криворотько
П. В. Криворотько
EIEvgeny N. Imyanitov
Evgeny N. Imyanitov
RDR. V. Donskih
R. V. Donskih
ASAnna Sokolenko
Anna Sokolenko
VSV. F. Semiglazov
V. F. Semiglazov
Rationale. BRCA1 associated triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer. At the same time, carcinomas that develop in carriers of BRCA1 mutations are characterized by extremely high sensitivity to DNA-damaging chemotherapy. Mitomycin C alone or in combination with platinum agents has already demonstrated promising results in the treatment of BRCA-associated ovarian cancer (OC) and metastatic breast cancer. In this article, we present the results of a retrospective study aimed at comparing standard neoadjuvant chemotherapy regimens (NACT) with mitomycin-based regimens for primary locally advanced BRCA1-associated TNBC.The aim of the study is to determine the effectiveness of the combination of mitomycin and platinum compounds during neoadjuvant therapy in patients with primary locally advanced BRCA1 – associated TNBC.Materials and methods. The study included 89 patients diagnosed with primary locally advanced BRCA1-associated TNBC. Patients were divided into three groups depending on the therapy: 1) 4 cycles of anthracycline and cyclophosphamide followed by 12 weekly injections of paclitaxel (n = 48) (AC + T), 2) 4 cycles of anthracycline and cyclophosphamide followed by 12 weekly injections of paclitaxel and carboplatin (n = 27) (AC + TCbP), 3) mitomycin C plus platinum followed by 12 weekly injections of paclitaxel (n = 14) (MR + T). Pathological complete response (pCR) rates were compared.Results. The pCR rate in the MP+T group was 10/14 (71%). In patients with BRCA1-associated breast cancer who received AC + T and AC + TCbP regimens as NACT, the pCR rate was 17/48 (35%) and 19/27 (70%), respectively. The difference in pCR rate between mitomycin-containing therapy and the standard AC + T regimen was statistically significant (p = 0.03); the frequency of regressions was comparable to the frequency in the AC + TCbP group. During the 20-month follow-up period, no relapses were observed in the MR + T group. Relapses were more frequent in the AC + T group compared with the AC + TCbP group (16/48 (33%) vs 1/27 (4%), p = 0.003, Fisher’s exact test). The toxicity profile of the mitomycin-containing regimen included hematologic adverse events, the most common of which were anemia and leukopenia. Compared to standard regimens, nausea was significantly less pronounced. No patients reported alopecia with this regimen.Conclusions. The addition of mitomycin C to neoadjuvant therapy for BRCA1-associated TNBC may be a promising treatment option for this category of patients and merits further study.